pharma · Diabetes · Congenital Bleeding Disorder
Novo Nordisk A/S
NovaPharmaNews editorial coverage mentioning Novo Nordisk A/S — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Novo Alle, Bagsværd, 2880, DK
- Founded
- 1923
- Employees
- 63,033
- Programs
- 40
- Drugs
- 46
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Novo Nordisk A/S — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Novo Nordisk A/S — regulatory, clinical, and market analysis.
Weight Loss Medications in 2026: GLP-1 Market Shift
Novo wins UK approval as race to launch weight-loss pill intensifies
Novo Nordisk won UK approval for its oral Wegovy weight-loss pill, making the UK the first European market to allow access. The decision strengthens Novo’s lead in the oral GLP-1 race as Eli Lilly advances orforglipron.
Novo Nordisk supply of Wegovy stabilizes as new capacity comes online
Novo Nordisk says Wegovy supply is stabilizing as FDA-determined shortages of Wegovy and Ozempic are resolved. The company is also investing $4.1 billion to expand manufacturing capacity in Clayton, North Carolina.
Novo Nordisk supply of Wegovy stabilizes as FDA shortage ends
Novo Nordisk supply Wegovy stabilizes as the FDA says the shortage of Wegovy and Ozempic is resolved. The change follows new and planned manufacturing capacity, with implications for access, competition, and BD strategy.
Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
Novo Nordisk’s CagriSema phase 3 update shows strong obesity and diabetes efficacy, but the obesity readout fell short of top-tier expectations. This plan focuses on the catalyst, the comparator data, and what BD teams and investors should watch next.
Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst
Novo Nordisk’s CagriSema Phase 3 program produced 22.7% mean weight loss in REDEFINE 1, reinforcing the program as a major obesity catalyst. This plan frames the results, the next clinical milestones, and why BD and investor teams should track them.
US FDA Proposes New Regulations on Weight-Loss Drug Compounding
The FDA has proposed new regulations limiting the mass compounding of weight-loss drugs from Novo Nordisk and Eli Lilly. This move could reshape the competitive landscape for these pharmaceutical giants.
EMA Endorses Novo Nordisk's Wegovy for Weight Loss
The European Medicines Agency has endorsed Novo Nordisk's Wegovy for weight loss, marking a significant milestone in obesity treatment. This analysis explores the implications for investors and pharma teams.
AI Accelerates Novo Nordisk's Parkinson’s Cell Therapy
Novo Nordisk is leveraging AI to enhance its Parkinson's cell therapy development. This advancement could reshape the market landscape for investors and analysts.
Big Pharma Q1 Growth Insights: Lilly, AbbVie, J&J, AZ Lead the Charge
This article analyzes the recent Q1 growth trends in Big Pharma, focusing on key players and their market implications.